A trial to compare the effects of nebivolol versus atenolol on various cardiovascular measurements including insulin sensitivity - Nebivolol trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001214-40-GB

Enrollment

Registered

2007-08-01

Start date

2007-08-17

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Trade Name: Atenolol Product Name: Atenolol Pharmaceutical Form: Tablet Trade Name: Nebliet Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertension; BP =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Compelling indication for beta blockers Contra-indication to or previous intolerance of thiazide diuretics or beta blockers Asthma Diabetes Concurrent treatment with verapamil/diltiazem Heart Failure AV conduction disturbances Atrial fibrilation Co-existing clinically important conditions which may interfere with the study

Design outcomes

Primary

Measure	Time frame
Main Objective: To compare the effects of nebivolol and atenolol on insulin sensitivity ; Secondary Objective: To compare the effects of atenolol and nebivolol on: clinical and ambulatory blood pressure and heart rate erectile dysfunction weight forced expiratory volume HbA1c lipids cerebral blood flow ;Primary end point(s): Difference in insulin sensitivity index following eight weeks' treatment with atenolol and nebivolol	—

Measure

Time frame

Main Objective: To compare the effects of nebivolol and atenolol on insulin sensitivity ; Secondary Objective: To compare the effects of atenolol and nebivolol on: clinical and ambulatory blood pressure and heart rate erectile dysfunction weight forced expiratory volume HbA1c lipids cerebral blood flow ;Primary end point(s): Difference in insulin sensitivity index following eight weeks' treatment with atenolol and nebivolol

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026